1

1	Effect of gastroesophageal reflux disease on sleep disorders: a Mendelian randomization
2	study
3	Zijie Li <sup>1,2#</sup> , Weitao Zhuang <sup>1,3#</sup> , Junhan Wu <sup>1,2</sup> , Haijie Xu <sup>2,4</sup> , Yong Tang <sup>1</sup> , Guibin Qiao <sup>1,2</sup> *
4	
5	Author information
6	Affiliations:
7	<sup>1</sup> Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong
8	Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China
9	<sup>2</sup> Shantou University Medical College, Shantou 515041, China
10	<sup>3</sup> Department of Medical Oncology, State Key Laboratory of Oncology in South China,
11	Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center,
12	Guangzhou 510060, China
13	<sup>4</sup> Department of Thoracic Surgery, The First Affiliated Hospital of Shantou University
14	Medical College, Shantou 515041, China
15	<sup>#</sup> These authors contributed equally to this work.
16	
17	*Corresponding to:
18	Guibin Qiao, MD, PhD
19	Department of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong
20	Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China
21	guibinqiao@126.com
22	

2

### 23 Abstract

Background: Recently observational studies have consistently shown an association between gastroesophageal reflux disease (GERD) and sleep disorders. In this study, Mendelian randomization (MR) analysis was performed to determine the genetic causal relationship between GERD and the risk of sleep disorders.

28 Methods: The summary statistics of GERD and sleep disorders were obtained through 29 large-scale genome-wide association studies (GWAS). In addition to exploring sleep disorders, 30 a deeper analysis was conducted on some major categories of sleep disorders such as sleep 31 apnoea and insomnia. Various MR analysis methods including inverse-variance weighted 32 (IVW), MR Egger, weighted median, simple mode, and weighted mode were performed, and 33 the results of IVW were taken as the primary results. In addition, sensitivity analyses 34 including heterogeneity test and pleiotropy test were also performed to test the robustness of 35 the MR results.

**Results:** After removing the ineligible SNPs and the palindromic SNPs, IVW detected a significant effect of GERD on sleep disorders (OR = 1.436, 95% CI: 1.309-1.576, p = 2.099E-14) and sleep apnoea (OR = 1.486, 95% CI: 1.341-1.647, p = 4.409E-14). However, there was no genetic causality in the effect of GERD on insomnia (IVW OR = 1.146, 95% CI: 0.877-1.498, p = 0.319). Furthermore, the heterogeneity test and pleiotropy test found no evidence of bias, which indicated the results were robust.

42 Conclusions: Our study found that the presence of GERD increased the risk of sleep
43 disorders and sleep apnoea, but not the risk of insomnia. Further research is needed to identify
44 the specific mechanisms of causal relationships.

45									
46	Short title:	GERD and sleep di	isorders						
47									
48	Keywords:	gastroesophageal	reflux	disease;	sleep	disorders;	sleep	apnoea;	Mendelian
49	randomizati	on							
50									
51									
52									
53									
54									
55									
56									
57									
58									
59									
60									
61									
62									
63									
64									
65									
66									

4

#### 67

## 68 Background

Gastroesophageal reflux disease (GERD) is an illness describing the reflux of gastric contents into the esophagus. Acid regurgitation and heartburn are common uncomfortable symptoms of GERD [1]. Long-term GERD can lead to esophagitis and also increase the risk of esophageal cancer [1]. Approximately 13% of the general population worldwide suffer from GERD at least once a week [2].

74 Besides the esophageal symptoms, GERD has numerous extra-esophageal symptoms, 75 among which chronic cough and laryngitis are two well-known clinical manifestations [3]. 76 Remarkably, it has been indicated that there might be a strong correlation between GERD and 77 sleep disorders in many previous studies [4, 5], and the relationship might be bidirectional 78 [6-9]. GERD not only affects the objective sleep quality, but also may lead to the development 79 of obstructive sleep apnoea (OAS) and insomnia [4, 10]. On the one hand, previous studies 80 have shown that therapy for GERD could impair subjective sleep parameters and improve 81 sleep quality in patients with sleep disorders [4, 6, 11]. What is more, continuous positive 82 airway pressure treatment in patients with OSA has been shown to simultaneously improve 83 sleep quality and mitigate acid regurgitation [12].

There has been controversy regarding the bidirectional relationship between GERD and sleep disorders which needs to be urgently resolved. Recently, a study has genetically confirmed that sleep disorders such as insomnia and short sleep are risk factors for GERD [13]. However, the essential relationship between GERD and the risk of developing sleep disorders has not been robustly demonstrated. Moreover, existing observational

5

20	anidamiological findings may be influenced by confounding factors and reverse consults
89	epidemiological findings may be influenced by confounding factors and reverse causality,
90	making causal inference difficult [14]. It is of great significance to demonstrate the causal
91	relationship between GERD and sleep disorders, which is particularly relevant for the
92	adjustment of clinical interventions.
93	It is impractical and unethical to evaluate the effect of GERD on sleep disorders by
94	randomized controlled trials (RCTs), even though they are the best causal inference method in
95	etiology. Mendelian randomization (MR) analysis uses single nucleotide polymorphisms
96	(SNPs) as proxies of exposure to assess the effect on outcome [15, 16]. Genetic instrumental
97	variables (IVs) are assumed to affect outcome only through exposure, without confounding
98	factors. Therefore, MR analysis is less influenced by reverse causality and confounders [17].
99	This study aims to explore the potential causal association between genetic liability for GERD
100	and the risk of sleep disorders through MR analysis.
100 101	and the risk of sleep disorders through MR analysis.
	and the risk of sleep disorders through MR analysis. Methods
101	
101 102	Methods
101 102 103	Methods Study design
101 102 103 104	Methods Study design Our study followed the newly generated STROBE-MR statement for reporting MR
101 102 103 104 105	Methods Study design Our study followed the newly generated STROBE-MR statement for reporting MR research [18]. The basic process of MR analysis was shown in Figure 1. In this study, we set
101 102 103 104 105 106	Methods Study design Our study followed the newly generated STROBE-MR statement for reporting MR research [18]. The basic process of MR analysis was shown in Figure 1. In this study, we set GERD and sleep disorders as exposure and outcome, respectively. The genetic information of
101 102 103 104 105 106 107	Methods Study design Our study followed the newly generated STROBE-MR statement for reporting MR research [18]. The basic process of MR analysis was shown in Figure 1. In this study, we set GERD and sleep disorders as exposure and outcome, respectively. The genetic information of GERD derived from a genome-wide association study (GWAS) was set as IVs.

6

111	[19]. For sleep disorders, there are seven main categories of sleep disorders [20]. Previous
112	observational studies have shown that GERD has an impact on sleep disorders, particularly on
113	sleep apnoea and insomnia [4, 10]. Therefore, in addition to exploring sleep disorders, we
114	have also analyzed several major categories of sleep disorders such as sleep apnoea and
115	insomnia for a deeper analysis. GWAS summary statistics for several aforementioned
116	phenotypes were obtained from the FinnGen Consortium (Table 1). All the GWAS summary
117	data applied in this study can be obtained from the IEU open GWAS project
118	(https://gwas.mrcieu.ac.uk/).

### 119 Selection of IVs

120 MR is based on three critical assumptions: (1) IVs are closely related to GERD; (2) IVs should not be affected by known or unknown confounding factors; and (3) IVs only affect 121 122 sleep disorders through GERD [21]. The following standard procedures were used to select 123 the best IVs, which ensured the integrity and accuracy of the results. First, SNPs that reached the genome-wide significant threshold (p  $< 5 \times 10^{-8}$ ) were extracted. To ensure the 124 independence of IVs, a clumping process ( $r^2 < 0.001$  and distance > 10,000 kb) was 125 126 performed, which used linkage disequilibrium (LD) estimates calculated from Europeans in 127 the 1000 Genomes project [22]. Second, ensuring that there is no association between the 128 instrumental SNPs and confounding factors, which was identified through the PhenoScanner database [23]. Third, the GERD SNPs that were closely associated ( $p < 5 \times 10^{-5}$ ) with sleep 129 130 disorders were considered ineligible SNPs and were further excluded. Furthermore, F-statistics is the measurement of the strength of IVs, which equals to  $R^2 \times (N-2) \div (1-R^2)$ , 131 where  $R^2$  refers to the proportion of exposure variability explained by each IV and N refers to 132

7

133	the sample size of the GWAS for exposure [24]. $R^2$ is calculated by the equation: $2 \times EAF \times$
134	$(1 - EAF) \times Beta^2$ , which used to represent the proportion of variance in an exposure factor
135	explained by the IVs. EAF is the effect allele frequency and Beta represents the estimated
136	genetic effect on the risk of GERD [25]. F-statistics > 10 are typically used as the cutoff for
137	powerful IVs, and F-statistics less than 10 usually indicate the weak instrument bias [26].
138	MR analysis methods
138 139	MR analysis methods In this study, the inverse variance weighted (IVW) method was conducted as the primary
139	In this study, the inverse variance weighted (IVW) method was conducted as the primary

143 which enhanced the reliability of causal results [27]. If the estimates direction of the above

MR methods were significantly similar, it indicated that the causal effect of GERD on sleepdisorders was stable and reliable.

## 146 Sensitivity analysis

147 The Cochrane's Q test was used to assess heterogeneity between SNPs in the IVW 148 method. It was considered that there was no heterogeneity in the causal analysis when the 149 p-value  $\supseteq \ge \square 0.05$  [28]. Meanwhile, the random-effects IVW test was utilized to provide a 150 more conservative yet robust estimate when heterogeneity exists (p < 0.05). The MR 151 Pleiotropy RESidual Sum and Outlier (MR-PRESSO) test was applied to detect potential 152 horizontal pleiotropy and correct it by removing outlier SNPs [29]. In addition, the 153 leave-one-out analysis was performed to evaluate the reliability of the affiliation between the 154 SNPs and GERD, evaluating whether any SNP was responsible for the significant results. The

8

155	funnel plot was also used to detect the heterogeneity, and a symmetry plot indicated the
156	absence of heterogeneity. The results are assumed to be robust when the heterogeneity and
157	pleiotropy of the results do not exist. All statistical analyses were performed in R software
158	v4.0.0 (R Core Team 2020) with the "TwoSampleMR" v0.6.0 package, and the "MRPRESSO"
159	v1.0 package. The forest plot figure was generated in the "forestplot" v3.11 package.
160	
161	Results
162	MR analysis
163	After removing the ineligible SNPs and the palindromic SNPs, the remaining SNPs were
164	used for the subsequent MR analysis (Supplemental Table 1-3). All the F-statistics were
165	greater than 10 (ranging from 208 to 669), indicating no evidence of weak instrument bias. As
166	shown in figure 2, the IVW analysis exhibited an increased risk of sleep disorders in patients
167	with GERD ( $p = 2.099E-14$ ). Meanwhile, the estimates from MR Egger ( $p = 0.237$ ), weighted
168	median (p = $3.629E-09$ ), simple mode (p = $8.889E-03$ ), and weighted mode (p = $5.209E-03$ )
169	showed a consistent direction of the IVW estimate. In addition, IVW analysis also observed a
170	causal relationship between GERD and sleep apnoea ( $p = 4.409E-14$ ), and other MR analysis
171	methods were also statistically consistent. However, there is no causal relationship between
172	GERD and insomnia (IVW OR = 1.146, 95% CI: 0.877-1.498, p = 0.319).
173	Sensitivity analyses
174	According to the result of Cochran's Q test, there was no heterogeneity observed in MR
175	Egger and IVW (Table 2). The Egger-intercepts of MR-Egger analyses were not statistically

176 significantly different from zero (p = 0.986, p = 0.609, and p = 0.965), and directional

9

horizontal pleiotropy was not detected, which meant the SNPs of GERD do not affect the
incidence of sleep disorders, sleep apnoea, and insomnia through traits other than GERD. The
MR-PRESSO test did not detect any horizontal pleiotropy among the instrumental SNPs
either (Table 2).

MR regression slopes showed positive correlations between the effect of SNP on GERD and sleep disorders as well as sleep apnoea (Figure 3). The results of the leave-one-out analysis demonstrated that the risk estimates of genetically predicted GERD on sleep disorders, sleep apnoea, and insomnia were remarkably stable after leaving out one SNP at a time (Supplemental Figure 1). Moreover, the forest plots and funnel plots also showed that there was no significant heterogeneity of the instrumental variable SNPs (Supplemental Figure 2,3)

188

#### 189 **Discussion**

190 It is challenging to confirm the causal relationship between GERD and the risk of sleep 191 disorders without long-term prospective studies and RCTs. Although previous observational 192 studies have found a high prevalence of sleep disorders in patients with GERD, the results of 193 these studies are susceptible to confounders as well as reverse causation, which may affect the 194 robustness of the inferred conclusions. This study provided a genetically potential causal 195 proof that patients with GERD have a greater risk of sleep disorders and sleep apnoea, which 196 strongly confirmed the results of previous observational studies and contributed to clinical 197 strategy optimization.

198 Sleep disorders as well as sleep apnoea may be primarily associated with nocturnal

10

199 GERD rather than daytime GERD. A previous large-scale observational study has shown that 200 nocturnal gastroesophageal reflux symptom and sleep disorders were both highly prevalent 201 among patients with GERD (88.9% and 68.3%, respectively). Patients with nocturnal GERD 202 symptoms were 50% more likely to suffer from sleep disorders than those with GERD 203 symptoms only during the day [5]. Similarly, Ossur Ingi Emilsson et al. also found that the 204 patients with nocturnal GERD had more OSA symptoms than the patients without nocturnal 205 GERD [30]. Furthermore, the treatment of nocturnal GERD including proton-pump inhibitors 206 has been shown to improve both subjective and objective sleep measurements [8, 11]. The 207 above evidence revealed that nocturnal gastroesophageal reflux symptoms may be a major 208 risk factor for sleep disorders in patients with GERD.

209 GERD symptoms negatively affect the quality of sleep and cause sleep disorders. Kindt S 210 et al. found that 84% of reported sleep disorders were attributed to nocturnal GERD, and the 211 main causes of sleep disorders due to GERD included reflux in the supine position (72%), 212 typical reflux disturbing sleep (39%), and waking because of reflux (45%), among 9322 213 patients with heartburn or regurgitation [31]. In addition, Jui-Sheng Hung et al. indicated that 214 increased nocturnal acid reflux may play a role in inducing sleep disorders in patients with 215 GERD [32]. Normally, gravity and peristaltic clearance of esophageal reflux can limit the 216 contact time between esophageal acid and mucosa. In contrast, during recumbent sleep, the 217 beneficial effect of gravity is lost. Meanwhile, salivation and swallowing are dramatically 218 decreased and peristalsis of esophageal wall is repressed, especially during deep sleep, which 219 can lead to prolonged acid contact in the esophagus and favor upward migration of refluxate 220 into the proximal esophagus during sleep [33]. When gastroesophageal reflux occurred during

11

sleep, it might cause heartburn sensations, which may interfere with sleep and lead to sleep disorders. Moreover, the severity of sleep disorders is closely related to the severity of nocturnal acid reflux and esophageal pH changes [34]. Furthermore, a significant proportion of people with GERD are more likely to have accompanying conditions such as functional dyspepsia and irritable bowel syndrome, which affected the quality of life and might have an impact on sleep disorders [35].

227 Notably, multiple mechanisms may exist between GERD and the high risk of sleep 228 apnoea, mainly including the vagal reflex, and the repetitive microaspiration of refluxed 229 gastric acid by the respiratory tract. Most patients with GERD have nocturnal acid reflux 230 symptoms because the lying position during sleep can lead to the migration of gastric acid and 231 aspiration into the respiratory tract [36]. During the sleep period, the refluxed gastric acid in 232 the distal esophagus might trigger the vagal reflex, which facilitates bronchospasm, 233 vasodilatation and mucus secretion, resulting in airway stenosis and obstruction [37]. The 234 migration of refluxed gastric contents and microaspiration of acid also could cause 235 inflammation and edema of the upper airway, as well as bronchoconstriction, thereby 236 predisposing to OSA.

This was the first MR study to illustrate the causal relationship between GERD and the high risk of sleep disorders. The current study had several strengths. First, the MR study is different from the observational study in that genetic associations can be obtained from large-scale GWAS, which can significantly improve the statistical efficacy of causal relationship. Second, the MR study is not susceptible to confounding factors and reverse causality that are commonly seen in observational studies. Third, the sensitivity analysis

including the heterogeneity test and pleiotropy test can verify the robustness of the results,

- thereby strengthening the evidence for our findings.
- 245 Despite the validity and robustness of our findings, the current study had some limitations.
- Firstly, although GERD was associated with the risk of insomnia in observational studies [10],
- 247 the results of MR analysis were not statistically significant, especially the IVW method,
- which needed further study to explore the causal relationship between GERD and insomnia.
- 249 Moreover, since the GWAS data used in the study were derived from European populations, it
- 250 might limit the generalization of the conclusion to non-European populations. It would be
- 251 helpful to provide more valid conclusions by including more GERD-associated SNPs and a
- 252 larger sample of more ethnicities. Finally, potential sample overlap might be another source of
- 253 bias. However, the F-statistics calculated for all SNPs were sufficiently large (ranging from
- 254 208 to 669), suggesting that the bias might be minimal [38].
- 255

## 256 Conclusions

Our MR study suggests that GERD is an important risk factor for sleep disorders and sleep apnoea, whereas we have found no evidence to support an association between GERD and the risk of insomnia, which may require further study to verify.

260

### 261 Availability of data and materials

262 The datasets presented in the current study can be found in online repositories.

263

# 264 Abbreviations

- 265 GERD = Gastroesophageal reflux disease
- 266 OAS = Obstructive sleep apnoea
- 267 RCTs = Randomized controlled trials
- 268 MR = Mendelian randomization
- 269 SNPs = Single nucleotide polymorphisms
- 270 IVs = instrumental variables
- 271 GWAS = Genome-wide association study
- 272 LD = linkage disequilibrium
- 273 IVW = Inverse variance weighted
- 274 MR-PRESSO = MR Pleiotropy RESidual Sum and Outlier
- 275 CI = Confidence intervals
- OR = Odds ratio
- 277

## 278 Acknowledgments

- 279 The authors acknowledged Jue-Sheng Ong et al. for their contribution, as well as the effort of
- the FinnGen Consortium in providing high-quality GWAS data for researchers.
- 281
- 282 Ethics declarations
- 283 Ethical approval and consent to participate
- 284 The GWAS summary data used in this study were obtained from published studies that have
- 285 been approved by institutional review boards in their respective studies.
- 286 **Consent for publication**

14

# 287 Not applicable.

## 288 Competing interests

289 The authors declare that they have no competing interests.

290

## 291 Authors contribution:

292 Study project conception: Guibin Qiao and Zijie Li. Research project organization and

execution: Weitao Zhuang and Yong Tang. Data curation: Zijie Li, Junhan Wu, and Haijie Xu.

- 294 Statistical analysis, design, and execution: Zijie Li and Weitao Zhuang. Statistical analysis
- 295 review: Guibin Qiao and Yong Tang. Writing of the first draft: Zijie Li, Weitao Zhuang,
- 296 Junhan Wu, and Haijie Xu. Manuscript review: Guibin Qiao and Yong Tang. Yong Tang and
- 297 Guibin Qiao take responsibility for the data integrity.

298

299 Funding: This study was funded by a grant from the Science and Technology Program of

300 Guangzhou, China (202206010103); and the Natural Science Foundation of Guangdong
301 Province (2022A1515012469).

302

# 303 References

- 304 1. Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal Reflux Disease. JAMA.
  305 2020;324(24):2565. doi:10.1001/jama.2020.21573
- 306 2. Richter JE, Rubenstein JH. Presentation and Epidemiology of Gastroesophageal Reflux
- 307 Disease. *Gastroenterology*. 2018;154(2):267-276. doi:10.1053/j.gastro.2017.07.045

15

308	3. Sidhwa F, Moore A, Alligood E, Fisichella PM. Diagnosis and Treatment of the
309	Extraesophageal Manifestations of Gastroesophageal Reflux Disease. Ann Surg.
310	2017;265(1):63-67. doi:10.1097/SLA.000000000001907
311	4. Oh JH. Gastroesophageal reflux disease: recent advances and its association with sleep.
312	Ann N Y Acad Sci. 2016;1380(1):195-203. doi:10.1111/nyas.13143
313	5. Mody R, Bolge SC, Kannan H, Fass R. Effects of gastroesophageal reflux disease on sleep
314	and outcomes. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc.

- 315 2009;7(9):953-959. doi:10.1016/j.cgh.2009.04.005
- 316 6. Fujiwara Y, Arakawa T, Fass R. Gastroesophageal reflux disease and sleep disturbances. J
- 317 *Gastroenterol*. 2012;47(7):760-769. doi:10.1007/s00535-012-0601-4
- 318 7. Fass R. Effect of gastroesophageal reflux disease on sleep. J Gastroenterol Hepatol.
- 319 2010;25 Suppl 1:S41-44. doi:10.1111/j.1440-1746.2009.06210.x
- 320 8. Shibli F, Skeans J, Yamasaki T, Fass R. Nocturnal Gastroesophageal Reflux Disease
- 321 (GERD) and Sleep: An Important Relationship That Is Commonly Overlooked. J Clin

322 *Gastroenterol*. 2020;54(8):663-674. doi:10.1097/MCG.00000000001382

- 323 9. Vernia F, Di Ruscio M, Ciccone A, et al. Sleep disorders related to nutrition and digestive
- 324 diseases: a neglected clinical condition. *Int J Med Sci.* 2021;18(3):593-603.
  325 doi:10.7150/ijms.45512
- 326 10. Lindam A, Ness-Jensen E, Jansson C, et al. Gastroesophageal Reflux and Sleep

16

327	Disturbances: A Bidirectional Association in a Population-Based Cohort Study, The HUNT

- 328 Study. *Sleep*. 2016;39(7):1421-1427. doi:10.5665/sleep.5976
- 329 11. Regenbogen E, Helkin A, Georgopoulos R, Vasu T, Shroyer ALW. Esophageal reflux
- disease proton pump inhibitor therapy impact on sleep disturbance: a systematic review.
- 331 Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg.
- 332 2012;146(4):524-532. doi:10.1177/0194599812436933
- 333 12. Tamanna S, Campbell D, Warren R, Ullah MI. Effect of CPAP Therapy on Symptoms of
- 334 Nocturnal Gastroesophageal Reflux among Patients with Obstructive Sleep Apnea. J Clin
- 335 Sleep Med JCSM Off Publ Am Acad Sleep Med. 2016;12(9):1257-1261.
- 336 doi:10.5664/jcsm.6126
- 337 13. Sun Y, Cao X, Cao D, et al. Genetic estimation of correlations and causalities between
  338 multifaceted modifiable factors and gastro-oesophageal reflux disease. *Front Nutr.*339 2022;9:1009122. doi:10.3389/fnut.2022.1009122
- 340 14. Greenland S, Robins JM. Confounding and misclassification. Am J Epidemiol.
  341 1985;122(3):495-506. doi:10.1093/oxfordjournals.aje.a114131
- 342 15. Burgess S, Labrecque JA. Mendelian randomization with a binary exposure variable:
- interpretation and presentation of causal estimates. *Eur J Epidemiol*. 2018;33(10):947-952.
- 344 doi:10.1007/s10654-018-0424-6
- 16. Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Davey Smith G. Mendelian
  randomization: using genes as instruments for making causal inferences in epidemiology.

### 347 Stat Med. 2008;27(8):1133-1163. doi:10.1002/sim.3034

- 348 17. Burgess S, Timpson NJ, Ebrahim S, Davey Smith G. Mendelian randomization: where
  349 are we now and where are we going? *Int J Epidemiol.* 2015;44(2):379-388.
  350 doi:10.1093/ije/dyv108
- 18. Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the Reporting of
- 352 Observational Studies in Epidemiology Using Mendelian Randomization: The
- 353 STROBE-MR Statement. JAMA. 2021;326(16):1614-1621. doi:10.1001/jama.2021.18236
- 19. Ong JS, An J, Han X, et al. Multitrait genetic association analysis identifies 50 new risk
- 355 loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides
- insights into clinical heterogeneity in reflux diagnosis. *Gut.* 2022;71(6):1053-1061.
- 357 doi:10.1136/gutjnl-2020-323906
- 358 20. Sateia MJ. International classification of sleep disorders-third edition: highlights and
- 359 modifications. *Chest.* 2014;146(5):1387-1394. doi:10.1378/chest.14-0970
- 360 21. Emdin CA, Khera AV, Kathiresan S. Mendelian Randomization. *JAMA*.
   361 2017;318(19):1925-1926. doi:10.1001/jama.2017.17219
- 362 22. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal
- inference across the human phenome. Loos R, ed. *eLife*. 2018;7:e34408.
  doi:10.7554/eLife.34408
- 365 23. Kamat MA, Blackshaw JA, Young R, et al. PhenoScanner V2: an expanded tool for

18

366	searching	human	genotype-phenotype	associations.	Bioinformatics.
367	2019;35(22):4	4851-4853. d	oi:10.1093/bioinformatics/	btz469	

- 24. Palmer TM, Lawlor DA, Harbord RM, et al. Using multiple genetic variants as
  instrumental variables for modifiable risk factors. *Stat Methods Med Res.*2012;21(3):223-242. doi:10.1177/0962280210394459
- 25. Park JH, Wacholder S, Gail MH, et al. Estimation of effect size distribution from
  genome-wide association studies and implications for future discoveries. *Nat Genet*.
- 373 2010;42(7):570-575. doi:10.1038/ng.610
- 374 26. Burgess S, Thompson SG. Bias in causal estimates from Mendelian randomization
  375 studies with weak instruments. *Stat Med.* 2011;30(11):1312-1323. doi:10.1002/sim.4197
- 27. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the
- 377 MR-Egger method. *Eur J Epidemiol*. 2017;32(5):377-389. doi:10.1007/s10654-017-0255-x
- 28. Greco M FD, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian
- 379 randomisation studies with summary data and a continuous outcome. *Stat Med*.
  380 2015;34(21):2926-2940. doi:10.1002/sim.6522
- 381 29. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in
- 382 causal relationships inferred from Mendelian randomization between complex traits and
- 383 diseases. *Nat Genet*. 2018;50(5):693-698. doi:10.1038/s41588-018-0099-7
- 384 30. Emilsson OI, Janson C, Benediktsdóttir B, Júlíusson S, Gíslason T. Nocturnal

19

385	gastroesophageal reflux, lung function and symptoms of obstructive sleep apnea: Results
386	from an epidemiological survey. Respir Med. 2012;106(3):459-466.
387	doi:10.1016/j.rmed.2011.12.004
388	31. Kindt S, Imschoot J, Tack J. Prevalence of and impact of pantoprazole on nocturnal
389	heartburn and associated sleep complaints in patients with erosive esophagitis. Dis
390	Esophagus Off J Int Soc Dis Esophagus. 2011;24(8):531-537.
391	doi:10.1111/j.1442-2050.2011.01189.x
392	32. Hung JS, Lei WY, Yi CH, Liu TT, Chen CL. Association Between Nocturnal Acid Reflux
393	and Sleep Disturbance in Patients With Gastroesophageal Reflux Disease. Am J Med Sci.
394	2016;352(2):141-145. doi:10.1016/j.amjms.2016.05.017
395	33. Lim KG, Morgenthaler TI, Katzka DA. Sleep and Nocturnal Gastroesophageal Reflux:
396	An Update. CHEST. 2018;154(4):963-971. doi:10.1016/j.chest.2018.05.030
397	34. Karoui S, Chtara O, Bibani N, et al. [Sleep disorders in patients with gastroesophageal
398	reflux disease: an open clinical and pH metric prospective study]. Tunis Med.
399	2010;88(3):172-177.
400	35. De Vries DR, Van Herwaarden MA, Baron A, Smout AJPM, Samsom M. Concomitant
401	functional dyspepsia and irritable bowel syndrome decrease health-related quality of life in
402	gastroesophageal reflux disease. Scand J Gastroenterol. 2007;42(8):951-956.
403	doi:10.1080/00365520701204204

404 36. Orr WC, Heading R, Johnson LF, Kryger M. Review article: sleep and its relationship to

405	gastro-oesophageal	reflux.	Aliment	Pharmacol	Ther.	2004;20	Suppl	9:39-46.
406	doi:10.1111/j.1365-2	2036.2004	.02239.x					
407	37. Canning BJ, Mazz	zone SB.	Reflex m	echanisms in	gastroes	sophageal	reflux di	sease and
408	asthma. Am J Med. 2	2003;115	Suppl 3A:4	45S-48S. doi:	10.1016/	s0002-934	3(03)001	92-x
409	38. Pierce BL, Burgess	s S. Effici	ent Design	n for Mendelia	in Rando	omization S	Studies: S	Subsample
410	and 2-Sample Instru	mental V	ariable Est	timators. Am .	I Epiden	niol. 2013;	178(7):1	177-1184.
411	doi:10.1093/aje/kwt0	)84						

412

### 413 Tables

## 414 Table 1. Basic information on the GWAS applied in this study.

Year	Trait	Consortium	Population	Sample size	N-case	N-control	Number of SNPs
2021	Gastroesophageal reflux	PMID: 34187846	European	602,604	129,080	473,524	2,320,781
	disease						
2021	sleep disorders	FinnGen	European	216,700	19,155	197,545	16,380,458
2021	sleep apnoea	FinnGen	European	217,955	16,761	201,194	16,380,465
2021	insomnia	FinnGen	European	217,855	1,691	216,164	9,851,867

415 SNPs, Single nucleotide polymorphisms.

416

417 Table 2. Heterogeneity pleiotropy test of GERD genetic IVs for sleep disorders.

Heterogeneity test

Pleiotropy test

Outcomes	MR Egger			Inverse variance weighted			MR Egger			PRESSO
	Q	Q_df	P value*	Q	Q_df	P value*	intercept	SE	P value*	P value*
sleep disorders	74.49	71	0.366	74.49	72	0.397	0.0001	0.009	0.986	0.456
sleep apnoea	79.27	71	0.234	79.57	72	0.253	-0.0055	0.011	0.609	0.310
insomnia	60.62	73	0.849	60.63	74	0.868	-0.0012	0.026	0.965	0.867

418 \*P value  $\geq 0.05$  represents no significant heterogeneity or pleiotropy.

419

```
420 Figures
```

- 421 Figure 1. Flow chart of this study. SNPs, single-nucleotide polymorphisms; LD, linkage
- 422 disequilibrium.
- 423 Figure 2. Mendelian randomization estimates of the associations between GERD and the risk
- 424 of sleep disorders. IVW, Inverse variance weighted.
- 425 Figure 3. Scatter plots of the effect size of each SNP on GERD and sleep disorders. (A) sleep


426 disorders, (B) sleep apnoea, (C) insomnia. GERD, Gastroesophageal reflux disease.

427

# 428 Supplementary Information

- 429 Supplemental Table 1. SNPs used as instrumental variables of GERD on sleep disorders.
- 430 Supplemental Table 2. SNPs used as instrumental variables of GERD on sleep apnoea.
- 431 Supplemental Table 3. SNPs used as instrumental variables of GERD on insomnia.
- 432 Supplemental Figure 1. Leave-one-out analysis of GERD on sleep disorders.
- 433 Supplemental Figure 2. Forest plots of each SNPs effect for GERD on sleep disorders and all
- 434 estimates.

435 Supplemental Figure 3. Funnel plot of SNPs of GERD on sleep disorders.



Outcome	Method	nSNP		OR (95% CI)	P_value
Sleep disorders					
	IVW	73	-	1.436 (1.309-1.576)	p = 2.099E-14
	MR Egger	73	ı <b>↓</b> ∎−−−i	1.429 (0.795-2.567)	p = 0.237
	Weighted median	73	H <b>H</b> H	1.501 (1.315-1.713)	p = 3.629E-09
	Simple mode	73	<b>⊷</b> ∎⊶	1.579 (1.132-2.203)	p = 8.889E-03
	Weighted mode	73	<b>⊷</b> ∎⊶	1.596 (1.161-2.194)	p = 5.209E-03
Sleep apnoea					
	IVW	73		1.486 (1.341-1.647)	p = 4.409E-14
	MR Egger	73	<b>↓</b>	1.758 (0.919-3.362)	p = 9.250E-02
	Weighted median	73	H <b>H</b> H	1.420 (1.227-1.645)	p = 2.777E-06
	Simple mode	73	<b>⊢</b> ∎1	1.378 (0.980-1.938)	p = 6.896E-02
	Weighted mode	73	<b>⊢</b> ∎1	1.378 (1.011-1.879)	p = 4.586E-02
insomnia					
	IVW	75	<b>⊷</b>	1.146 (0.877-1.498)	p = 0.319
	MR Egger	75	▶ <b></b>	1.187 (0.245-5.756)	p = 0.832
	Weighted median	75	<b>⊢⊨</b> →	1.046 (0.700-1.562)	p = 0.826
	Simple mode	75	⊷ <mark>∎</mark> ↓4	0.854 (0.345-2.112)	p = 0.734
	Weighted mode	75	<b>⊢</b> ∎ <mark> </mark> →	0.819 (0.334-2.004)	p = 0.663
			0 1 2 3 4 5 6 Odds Ratio (95% Cl)		

#### (A) sleep disorders

(B) sleep apnoea

#### (C) insomnia

